Real-time Estimate
Cboe BZX
12:02:16 2024-05-09 pm EDT
|
5-day change
|
1st Jan Change
|
15.09
USD
|
+4.07%
|
|
+0.26%
|
-19.47%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
391.2
|
1,632
|
872.1
|
467.6
|
1,356
|
1,156
|
-
|
-
|
Enterprise Value (EV)
1 |
391.2
|
1,497
|
709.3
|
414
|
1,356
|
884.2
|
758
|
743.9
|
P/E ratio
|
-7.12
x
|
-17.3
x
|
-6.92
x
|
-4
x
|
-9.45
x
|
-5.92
x
|
-7.48
x
|
-13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.1
x
|
106
x
|
46.3
x
|
14.1
x
|
-
|
-
|
28
x
|
7.21
x
|
EV / Revenue
|
19.1
x
|
97.2
x
|
37.7
x
|
12.5
x
|
-
|
-
|
18.3
x
|
4.64
x
|
EV / EBITDA
|
-
|
-17,529,769
x
|
-5,571,747
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-5.99
x
|
-23.3
x
|
-5.37
x
|
-3.1
x
|
-
|
-4.46
x
|
-3.64
x
|
-6.43
x
|
FCF Yield
|
-16.7%
|
-4.3%
|
-18.6%
|
-32.3%
|
-
|
-22.4%
|
-27.5%
|
-15.5%
|
Price to Book
|
-
|
6.36
x
|
5.3
x
|
2.07
x
|
-
|
5.61
x
|
4.55
x
|
4.75
x
|
Nbr of stocks (in thousands)
|
29,678
|
33,639
|
35,108
|
51,663
|
72,143
|
79,754
|
-
|
-
|
Reference price
2 |
13.18
|
48.53
|
24.84
|
9.050
|
18.80
|
14.50
|
14.50
|
14.50
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/7/22
|
3/7/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.49
|
15.4
|
18.82
|
33.19
|
-
|
-
|
41.31
|
160.4
|
EBITDA
|
-
|
-85.39
|
-127.3
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-54.54
|
-86.88
|
-129.9
|
-134.4
|
-171.3
|
-241.8
|
-222
|
-133.9
|
Operating Margin
|
-266.16%
|
-564.03%
|
-690.48%
|
-404.81%
|
-
|
-
|
-537.37%
|
-83.48%
|
Earnings before Tax (EBT)
1 |
-51
|
-86.48
|
-131.8
|
-134.5
|
-165.8
|
-237.5
|
-211.9
|
-143.6
|
Net income
1 |
-51
|
-86.48
|
-131.8
|
-134.5
|
-165.8
|
-237.5
|
-211.6
|
-107.8
|
Net margin
|
-248.88%
|
-561.47%
|
-700.46%
|
-405.21%
|
-
|
-
|
-512.23%
|
-67.21%
|
EPS
2 |
-1.850
|
-2.810
|
-3.590
|
-2.260
|
-1.990
|
-2.450
|
-1.938
|
-1.116
|
Free Cash Flow
1 |
-65.34
|
-64.36
|
-132
|
-133.8
|
-
|
-198.2
|
-208.3
|
-115.6
|
FCF margin
|
-318.87%
|
-417.83%
|
-701.73%
|
-402.97%
|
-
|
-
|
-504.19%
|
-72.08%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/7/22
|
3/7/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
4.049
|
33.19
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-38.35
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-35.36
|
-6.933
|
-43.15
|
-43.86
|
-40.43
|
-40.51
|
-39.08
|
-43.67
|
-48.03
|
-58.42
|
-59.27
|
-60.64
|
-62.12
|
-60.03
|
-63.4
|
Operating Margin
|
-873.4%
|
-20.89%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-35.91
|
-7.95
|
-44
|
-43.3
|
-39.26
|
-39.38
|
-37.92
|
-42.36
|
-46.13
|
-56.85
|
-58.78
|
-60.23
|
-61.63
|
-55.75
|
-59.68
|
Net income
1 |
-35.91
|
-7.95
|
-44
|
-43.3
|
-39.26
|
-39.38
|
-37.92
|
-42.36
|
-46.13
|
-56.85
|
-58.78
|
-60.23
|
-61.63
|
-55.75
|
-59.68
|
Net margin
|
-886.98%
|
-23.95%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9700
|
-0.2100
|
-1.060
|
-0.5500
|
-0.4600
|
-0.4900
|
-0.4700
|
-0.5300
|
-0.5000
|
-0.5900
|
-0.6275
|
-0.6350
|
-0.6025
|
-0.5750
|
-0.5900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/7/22
|
5/16/22
|
8/8/22
|
11/14/22
|
3/7/23
|
5/9/23
|
8/9/23
|
11/7/23
|
3/19/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
136
|
163
|
53.5
|
-
|
272
|
398
|
413
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-65.3
|
-64.4
|
-132
|
-134
|
-
|
-198
|
-208
|
-116
|
ROE (net income / shareholders' equity)
|
-
|
-46.3%
|
-60.9%
|
-62.2%
|
-
|
-76%
|
-70.1%
|
-9%
|
ROA (Net income/ Total Assets)
|
-
|
-29.6%
|
-38.1%
|
-40.6%
|
-
|
-55.8%
|
-54.1%
|
-7.24%
|
Assets
1 |
-
|
292.3
|
346.4
|
331.3
|
-
|
425.5
|
391.3
|
1,489
|
Book Value Per Share
2 |
-
|
7.640
|
4.690
|
4.370
|
-
|
2.580
|
3.190
|
3.050
|
Cash Flow per Share
|
-
|
-1.960
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
4.09
|
5.25
|
1.06
|
-
|
8.75
|
12.1
|
30.5
|
Capex / Sales
|
-
|
26.54%
|
27.89%
|
3.21%
|
-
|
-
|
29.17%
|
19.01%
|
Announcement Date
|
3/12/20
|
3/9/21
|
3/7/22
|
3/7/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
14.5
USD Average target price
26.25
USD Spread / Average Target +81.03% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.87% | 1.16B | | +2.93% | 108B | | -3.46% | 23.46B | | -14.60% | 21.72B | | -7.05% | 18.64B | | -38.55% | 17.45B | | -8.83% | 17.19B | | +5.51% | 13.99B | | +37.49% | 12.53B | | +329.39% | 8.81B |
Bio Therapeutic Drugs
|